



ABN 53 075 582 740

ASX ANNOUNCEMENT
12 January 2015

BIONOMICS CEO TO PRESENT AT BIOTECH SHOWCASE

Bionomics Limited (ASX:BNO, ADR:BMICY) today announced that CEO and Managing Director Dr Deborah Rathjen will present a company update at Biotech Showcase™ 2015 on Monday, 12th January 2015 at 9:00am PST at the Parc 55 Wyndham Hotel in San Francisco.

The three day event beginning today coincides with the 33rd Annual JP Morgan Healthcare Conference.

With a focus on investors and partnering, Biotech Showcase™ is expected to attract over 1,700 attendees from around the world. As well as biopharmaceutical executives other delegates include public and private investors, analysts, bankers and industry professionals.

The week of events in San Francisco is considered to be one of the largest and most important on the biotech calendar every year and briefings will also be given to US institutional investors and pharmaceutical companies.

The presentation from Dr Rathjen will highlight Bionomics strong financial position and robust pipeline of drug candidates for partnering and clinical development:

- Bionomics' US\$506 million partnership with Merck & Co. targeting cognition
- Bionomics' US \$172 million agreement with Merck & Co. targeting chronic and neuropathic pain
- Upcoming Phase I and Phase II trials of BNC210, in development for the treatment of anxiety and depression
- Progress in the oncology pipeline, including BNC101 which targets cancer stem cells.

The presentation will be given in the Mission II room at the Parc 55 Wyndham Hotel.

A copy of the presentation can be found on the Bionomics website www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications

Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group

Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.